Maybe best VALUE Health/Med Cannabis Opp EVER, page-5

I disagree. The company has a tiny market cap and already with AXIM a vast range of products at their disposal without the massive R & D spend.

Furthermore have you overlooked where they said they were looking to collaborate on development projects. This was made clearer in the AXIM press release.

I think cultivation is going to prove difficult to monetise and is in fact becoming unnecessary . Why have a grow room to cultivate a particular strain when modern extraction doesn’t require it?

I think the whole cultivation space will commoditise.

Ted